Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

4 Biotech Stocks Receiving Analyst Praise Thursday

|Includes: Aerie Pharmaceuticals, Inc. (AERI), AIMT, ARQL, TTOO

Corrupt politicians make the other ten percent look bad.” ― Henry Kissinger

The biotech sector had a nice rally on Wednesday.  The major biotech indices were up one to one and a half percent on the day.  We will try to keep the roll going today.

In the meantime, here are four biotech stocks garnering some analyst support this morning.

Let's start with T2 Biosystems (TTOO).  Cantor Fitzgerald reissues its Overweight rating and $10 price target on TTOO with the following commentary.

We reiterate our Overweight rating and 12-month PT of $10 on shares of TTOO. We conducted a 25-person survey of emergency medicine physicians all familiar with T2’s technology to understand physician perspective on T2 Bacteria. On average, our polled physicians think market penetration of T2 Bacteria will grow to 11.1% and 22.2% in one and two years from now, respectively. Significantly, 72% of respondents would clinically change the way he or she treats patients with T2 Bacteria. Physicians think T2 Bacteria is clinically appropriate for 65% of all patients suspected of sepsis, translating to an addressable $313MM annual sepsis diagnostic market.

RBC Capital initiates ArQule (ARQL) as a new Buy with a $9 price target.  RBC's analyst is 'positive on the company's "unique clinical portfolio of precision-based kinase inhibitors in oncology and orphan disease." and also expects that portfolio to appreciate over the year with additional clinical data for ARQ '531 inhibitor and progress on miransertib further de-risking the investment story'

Image result for Scale Clip Art On the Finger '10 Simple Rules To Trade Options Like A Pro' from our friends at Investors Alley is a good quick overview on using option strategies to mitigate risk and enhance returns in your portfolio. These strategies are well suited to high beta sectors like biotech where option premiums tend to be large. The report is now available free via download HERE

Oppenheimer maintains its Buy rating and $64 price target on Aerie Pharmaceuticals (AERI).  Here is their updated view.

We hosted investor meetings with AERI’s Vince Anido (NYSE:CEO) and Ami Bavishi (Director of IR), and remain excited about the prospects for the company in 2019. While investors discussed Rhopressa uptake and Rocklatan launch, we note growing interest in the pipeline and expansion opportunities. Overall, the discussions left us thinking the market may be warming up to the idea of AERI as the potential next major ophthalmic pharmaceutical company over the next several years. We maintain our Outperform rating and $64 PT, as we look forward to a dynamic year for AERI with revenues reaching $120M, increasing news flow on the pipeline and OUS activities, and a well-funded balance sheet that could facilitate opportunistic business development. Some takeaways below.”

A different analyst like Cantor Fitzgerald likes Aimmune (AIMT) this morning.  He reiterates his Overweight rating and $45 price target.  Here is his updated view

We reiterate our Overweight rating and 12-month price target of $45 on shares of AIMT. We recently hosted Aimmune management for investor meetings and came away with enhanced conviction about AR101 approvability and commercial prospects. Recently, Aimmune announced that the P3 ARTEMIS study in the EU met its primary endpoint (data at EAACI June 2), making it the only company to successfully complete two P3 studies in peanut allergy (PA), underscoring the “notable” efficacy of AR101 compared with other desensitization methods. The company also announced its BLA was accepted for review by the FDA, and we believe the process is now gaining traction.”

Politicians and diapers should be changed frequently, and for the same reason.” ― Eça de Queirós

Thank You & Happy Hunting,

Bret Jensen

Founder, The Biotech Forum, The Busted IPO Forum & The Insiders Forum

Image result for available now

We published an extensive free report on a new 7% yielding stock I just added to my personal portfolio late in March. The shares have recent insider buying as well. If you are signed up to receive our free reports, you should have received this research automatically in your email. If you want this investment analysis and are not registered yet, just go to and hit the 'free reports' tab to download this latest report. This action will also register you for all the free reports we put out going forward as published as well. Next week we look at a small biotech name with a fast approaching PDUFA date.